RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 ATLAS: 10 versus 5 Years of Adjuvant Tamoxifen in ER-Positive Disease
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 12
IS 20
SP 11
OP 12
DO 10.1177/155989771220008
UL http://mdc.sagepub.com/content/12/20/11.2.abstract
AB Treatment with tamoxifen for 5 years has substantially reduced the risk of breast cancer recurrence and death throughout the first 15 years after diagnosis of estrogen receptor (ER)-positive early breast cancer [Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2011]. The Adjuvant Tamoxifen: Longer Against Shorter [ATLAS] trial compared the effects of continuing tamoxifen for a total of 10 years with stopping after the standard 5 years of treatment. This article presents data from the ATLAS trial on the effect of tamoxifen on 15-year survival [Davies C et al. Lancet 2012].